


## Detailed analysis of accumulated losses

Date	11 May 2023
Name of the Listed Company	Gulf Pharmaceutical Industries PSC (Julphar)
Define the period of the financial statements	Quarter 1 – 2023
Value of the Accumulated losses	AED 254.2 million as of 31 March 2023
Accumulated losses to capital ratio	22.0% as of 31 March 2023
The main reasons leading to these accumulated losses and their history	The accumulated losses are from the prior years and the net loss for the period Q1 2023 contributed to the increase in accumulated losses.
Measures to be taken to address accumulated losses:	<p>The following measures were taken:</p> <ul style="list-style-type: none"> <li>● Regain market share of core products;</li> <li>● Restructure products portfolio and launch new products in the therapeutic areas in various markets; and</li> <li>● Implement further process improvements and productivity enhancement initiatives.</li> </ul>

The Name of the Authorized Signatory	Sheikh Saqr Humaid AlQasimi
Designation	Chairman 
Signature and Date	11 May 2023
Company's Seal	